497 related articles for article (PubMed ID: 10791375)
1. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
[TBL] [Abstract][Full Text] [Related]
2. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
International Collaboration on HIV and Cancer
J Natl Cancer Inst; 2000 Nov; 92(22):1823-30. PubMed ID: 11078759
[TBL] [Abstract][Full Text] [Related]
3. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
[TBL] [Abstract][Full Text] [Related]
4. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.
Lancet; 2000 Apr; 355(9210):1158-9. PubMed ID: 10791383
[TBL] [Abstract][Full Text] [Related]
5. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
6. Is AIDS a floating point between HIV seroconversion and death? Insights from the Tricontinental Seroconverter Study.
van Benthem BH; Veugelers PJ; Cornelisse PG; Strathdee SA; Kaldor JM; Shafer KA; Coutinho RA; van Griensven GJ
AIDS; 1998 Jun; 12(9):1039-45. PubMed ID: 9662201
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
[TBL] [Abstract][Full Text] [Related]
9. AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters.
Biggar RJ
AIDS; 1990 Nov; 4(11):1059-66. PubMed ID: 2282177
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with progression to AIDS and mortality in a cohort of HIV-infected patients with hemophilia followed up since seroconversion.
Santagostino E; Gringeri A; Cultraro D; Tradati F; Siracusano L; Marinoni A; Mannucci PM
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):371-80. PubMed ID: 7580830
[TBL] [Abstract][Full Text] [Related]
11. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
O'Brien TR; Blattner WA; Waters D; Eyster E; Hilgartner MW; Cohen AR; Luban N; Hatzakis A; Aledort LM; Rosenberg PS; Miley WJ; Kroner BL; Goedert JJ
JAMA; 1996 Jul; 276(2):105-10. PubMed ID: 8656501
[TBL] [Abstract][Full Text] [Related]
12. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.
Touloumi G; Karafoulidou A; Gialeraki A; Katsarou O; Milona I; Kapsimali V; Mandalaki T; Hatzakis A
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):89-97. PubMed ID: 9732075
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 disease progression and AIDS-defining disorders in rural Uganda.
Morgan D; Maude GH; Malamba SS; Okongo MJ; Wagner HU; Mulder DW; Whitworth JA
Lancet; 1997 Jul; 350(9073):245-50. PubMed ID: 9242801
[TBL] [Abstract][Full Text] [Related]
14. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
15. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
[TBL] [Abstract][Full Text] [Related]
16. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
d'Arminio Monforte A; Sabin CA; Phillips A; Sterne J; May M; Justice A; Dabis F; Grabar S; Ledergerber B; Gill J; Reiss P; Egger M;
Arch Intern Med; 2005 Feb; 165(4):416-23. PubMed ID: 15738371
[TBL] [Abstract][Full Text] [Related]
17. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
Clements M; Law M; Pedersen C; Kaldor J;
HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
[TBL] [Abstract][Full Text] [Related]
18. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up.
Glynn JR; Sonnenberg P; Nelson G; Bester A; Shearer S; Murray J
AIDS; 2007 Mar; 21(5):625-32. PubMed ID: 17314525
[TBL] [Abstract][Full Text] [Related]
19. Transfusion associated AIDS in Mexico. Clinical spectrum, conditional latency distribution, and survival.
Volkow P; Ponce de León S; Calva J; Ruiz-Palacios G; Mohar A
Rev Invest Clin; 1993; 45(2):133-8. PubMed ID: 8337540
[TBL] [Abstract][Full Text] [Related]
20. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
